Your email has been successfully added to our mailing list.

×
0.000477053716248558 0.00162198263524474 -0.00104951817574658 0.000477053716248558 0.000477053716248558 0.000477053716248558 0.000477053716248558 0.000477053716248558
Stock impact report

Ultragenyx gains Breakthrough Therapy status for setrusumab for genetic disorder Oct. 07, 2024 2:27 PM ET By: Jonathan Block , SA News Editor [Seeking Alpha]

Ultragenyx Pharmaceutical Inc. (RARE) 
Last ultragenyx pharmaceutical inc. earnings: 2/13 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.ultragenyx.com/investor-relations
Company Research Source: Seeking Alpha
) setrusumab for osteogenesis imperfecta, a group of rare genetic disorders impacting bone metabolism. Ultragenyx (RARE) said the status was granted based on data from the phase 2 portion of the Orbit study, which showed a rapid and clinically meaningful decrease in fracture rate in patients, as well as results from the phase 2b ASTEROID study. Setrusumab also has rare pediatric disease designation from the FDA, and was accepted into European Medicine Agency's Priority Medicines program (PRIME). More on Ultragenyx Pharmaceutical Ultragenyx's Strong Pipeline And Valuation Concerns: A Balanced Perspective Ultragenyx Pharmaceutical Inc. (RARE) Q2 2024 Earnings Call Transcript Ultragenyx Pharmaceutical Inc. 2024 Q2 - Results - Earnings Call Presentation Ultragenyx Pharmaceutical Q2 2024 Earnings Preview Ultragenyx to begin phase 3 study of Angelman syndrome asset by year end Recommended For You Comments More Trending News Recommended For You More Trending Show less Read more
Impact Snapshot
Event Time:
RARE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for RARE alerts
Opt-in for
RARE alerts

from News Quantified
Opt-in for
RARE alerts

from News Quantified